Combinations of antifungal agents in therapy–what value are they?
Open Access
- 1 November 2004
- journal article
- review article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 54 (5) , 854-869
- https://doi.org/10.1093/jac/dkh434
Abstract
Concurrent or sequential antifungal treatment for invasive mycoses has been typically considered as an option to improve results of monotherapy. However, data on the efficacy of combination therapy are sparse and consist largely of results from studies in vitro and experimental animal models. These studies have yielded controversial results depending on the criteria used to evaluate the antifungal interaction. Several combinations that showed synergy in vitro failed to do so in animal models. Overall, apart from cryptococcal infections, combined antifungal therapy is not significantly better than monotherapy in terms of clinical efficacy. It is questionable whether combination therapy should be used in most cases as there is a lack of evidence from well-designed clinical trials. However, combination therapy could be an alternative to monotherapy for patients with invasive infections that are difficult to treat, such as those due to multi-resistant species and for those who fail to respond to standard treatment.Keywords
This publication has 173 references indexed in Scilit:
- Review of Newer Antifungal and Immunomodulatory Strategies for Invasive AspergillosisClinical Infectious Diseases, 2003
- Combination antifungal therapy of murine aspergillosis: liposomal amphotericin B and micafunginJournal of Antimicrobial Chemotherapy, 2003
- Antifungal Activity of Nonantifungal DrugsEuropean Journal of Clinical Microbiology & Infectious Diseases, 2003
- Combined Antifungal Treatment of Visceral Mucormycosis with Caspofungin and Liposomal Amphotericin BEuropean Journal of Clinical Microbiology & Infectious Diseases, 2002
- Disseminated Zygomycosis in a Neutropenic Patient: Successful Treatment with Amphotericin B Lipid Complex and Granulocyte Colony-Stimulating FactorClinical Infectious Diseases, 1997
- A randomized study comparing fluconazole with amphotericin B/5-flucytosine for the treatment of systemicCandida infections in intensive care patientsInfection, 1996
- Antifungal combination therapy with granulocyte colony-stimulating factor and fluconazole in experimental disseminated candidiasisEuropean Journal of Clinical Microbiology & Infectious Diseases, 1995
- Amphotericin B versus amphotericin B plus 5-flucytosine: Poor results in the treatment of proven systemic mycoses in neutropenic patientsInfection, 1994
- In vitro susceptibility and synergy studies of Aspergillus species to conventional and new agentsDiagnostic Microbiology and Infectious Disease, 1992
- A Comparison of Amphotericin B Alone and Combined with Flucytosine in the Treatment of Cryptoccal MeningitisNew England Journal of Medicine, 1979